You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
he single-cell microbiome sequencing firm has raised a total of ¥1.5 billion in equity financing since its founding in 2018.
The Bay Area firm has built on its enzymatic barcoding technology to deliver a high-throughput, synthetic long-read library preparation technique.
The researchers noted that breast milk bacteria contributed to overall infant gut microbiota variation to a similar extent as other modifiers, such as birth mode.
A new analysis highlighted a decrease in the abundance of butyrate-producing bacteria among individuals with prediabetes or type 2 diabetes.
The University of Utah spinout said it will use the funding to enhance and expand its NGS-based Explify microbe identification platform and support its lab.
The companies are aiming to use microbial biomarkers to predict the development of precancerous adenomas and carcinomas.
Last week's SynBioBeta conference was indicative of the high degree of interest in the synthetic bio space from omics research tool vendors.
The San Francisco-based microbial genomics firm will sell off its product lines, testing labs, IP, and data within the next three months.
By analyzing metagenomic sequences found in thousands of human mouth and gut samples, researchers tracked down almost 45.7 million distinct microbial genes.
Researchers identified tumor microbe and immune differences in tumor samples from pancreatic ductal adenocarcinoma patients with exceptionally long survival.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.